Faculty Advisor

Olsen, Carissa Lynn

Abstract

This proposal explored new drug treatment plans for pancreatic cancer. The mTOR protein kinase activates a signaling network that effects cell growth substantially. Research has shown that unregulated mTOR activity is linked with cancer progression. Therefore, finding inhibitors of mTOR could halter cell growth, particularly those of cancer cells. AZD2014 is a selective inhibitor of the mTOR complex. DNA damage stimulators Doxorubicin, Olaparib, and Trametinib in combination treatments can cause serious cell cycle arrest and death in pancreatic cancer cells. Experiments were completed with pancreatic cancer cells to observe the results of how effective the drug combinations were through p-AKT, total AKT, and Chk-1 signal detection and cell viability.

Publisher

Worcester Polytechnic Institute

Date Accepted

April 2019

Major

Biochemistry

Project Type

Major Qualifying Project

Accessibility

Unrestricted

Advisor Department

Chemistry and Biochemistry

Share

COinS